Eisai and FORMA Therapeutics enter into broad drug discovery collaboration
WOODCLIFF LAKE, N.J.—Eisai Inc., the U.S. pharmaceutical subsidiary of Tokyo-based Eisai Co. Ltd., and FORMA Therapeutics have signed a strategic drug discovery collaboration. Under the terms of the agreement, Eisai will have non-exclusive access to FORMA's Diversity Oriented Synthesis (DOS) chemistry-generated compound library and cell-based screening platforms to support the discovery of novel compounds for Eisai's pipeline. In addition, Eisai has an option for technology transfer of FORMA's cell-based screening platform. FORMA will receive upfront payments and committed funding of $20 million over three years and is eligible to receive additional milestones plus royalties on future products that Eisai may commercialize as a result of this collaboration. Further details were not disclosed.